Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

.D., Chief Medical Officer at arGEN-X. "ARGX-111 is an excellent example of how our suite of antibody technologies enables us to generate exciting development candidates with multiple modes of action within a single therapeutic entity."

Ahmad Awada, M.D., Ph.D. of the Jules Bordet Institute, Brussels, Belgium, and Principal Investigator of the study, commented further: "The field of c-Met inhibition is one that offers significant promise in the fight against cancer. Therefore, we are very excited to be involved in the first ever clinical trial with ARGX-111, a potentially best-in-class molecule for the treatment of a broad range of solid and hematological cancers."

About the ARGX-111 Phase Ib Trial

The Phase Ib study being undertaken by arGEN-X includes an adaptive dose escalation scheme, to be followed by a safety cohort expansion.  Approximately 35 patients will be enrolled by a consortium of leading academic institutions in Belgium. In addition to traditional clinical and PK endpoints, biomarkers critical to understanding the effect of ARGX-111 on c-Met biology will be researched during the course of the trial.

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of high quality human antibodies, enabling optimal product choice. SIMPLE Antibodies™ are able to address and modulate any disease target
'/>"/>

SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... host a conference call and webcast on Thursday, August 7 ... 2014 financial results.  The call and webcast will follow the ... Conference Call Details To access the live conference ... phone, please dial (877) 303-7208 from the United ...
(Date:7/31/2014)... -- Celsion Corporation (NASDAQ: CLSN ) announced today ... discuss its second quarter 2014 financial results at 11:00 ... in the call, interested parties may dial 1-800-533-7954 (Toll-Free/ ... ask for the Celsion Corporation Second Quarter 2014 Conference ... the call is scheduled to begin. The call will ...
(Date:7/31/2014)... , 31. Juli 2014 Marken hat ... Miami bekanntgegeben, um die wachsenden logistischen ... Lateinamerika zu erfüllen. Die neu ausgebaute Einrichtung wird ... und für die Zusammenlegung von Sendungen in und ... Lagerkapazität bereitstellen.   Logo - ...
Breaking Medicine Technology:Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Celsion Corporation to Hold Second Quarter 2014 Financial Results 2Marken erweitert regionales Logistikzentrum in Miami 2
... Aug. 6 MicroDose Technologies,Inc., a privately ... announces top line results from a glucose ... MicroDose, through its joint venture with Vectura,Group ... efficient, rapid acting,insulin inhaler, based upon MicroDose,s ...
... today reported financial results for the quarter ended June ... $3.1 million, compared with,revenues of $7.3 million for the ... quarter of 2007 was $8.2 million, or $0.21 per ... $0.11 per share, for the second quarter,of 2006. The ...
Cached Medicine Technology:MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 2MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 3MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6
(Date:7/31/2014)... July 31, 2014 Insight Accelerator Labs ... Series A round of investment for $4.6 million to ... for collecting vital signs. The company joined Insight ... to fruition with the help of Insight development teams. ... reason for launching the Accelerator,” says Steve McPhilliamy, Executive ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement splint ... snorers airway to quiet snoring. , Dawn M. of Utah ... her husband by allowing them to share the same bedroom again. ... about 15 years ago and I remember nights when it was ... had to head downstairs for any relief. As the years have ...
(Date:7/31/2014)... rising steadily in the U.S in recent years. According ... the number of individuals reporting past year heroin use ... evidence suggests the increase may be linked to prescription ... PO use to heroin use, with POs providing the ... This drug-use trajectory appears to have become increasingly ...
(Date:7/31/2014)... CO (PRWEB) July 31, 2014 Ticket ... vs. Bolivia tickets at Dick’s Sporting Goods Park in ... years, the Mexican national soccer team has found a second ... and failures during their time playing international friendly games and ... Bolivia at Dick’s Sporting Goods Park in Commerce City, Colorado. ...
(Date:7/31/2014)... from Carnegie Mellon University have developed a novel ... reminiscent of fibers found in living cells. The ... materials for drug delivery and tissue engineering applications. ... issue of Angewandte Chemie International Edition . ... linkers to protein molecules, we can form completely ...
Breaking Medicine News(10 mins):Health News:Insight Accelerator Labs Advances Member Toward Commercialization 2Health News:Insight Accelerator Labs Advances Member Toward Commercialization 3Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:Carnegie Mellon chemists create nanofibers using unprecedented new method 2
... of 70 suffers from gait disturbance. To prevent falls, ... of Deutsches rzteblatt International, Klaus Jahn and ... Arztebl Int 107[17]: 306-16)., Gait disturbance is defined as ... slowing of old age. It often has multiple causes; ...
... Research also shows students are less aggressive and disruptive ... involvement in a child,s elementary school experience leads to ... new research suggests. , "The study shows that parents ... elementary school," the University of Pittsburgh research team said ...
... researchers at the University of Helsinki have found a mechanism ... of the brain for the information processing required later in ... science magazine The Journal of Neuroscience. The ... quite loosely interconnected. In the middle of chaos, they are ...
... hours, odds for good recovery decline sharply and risk of ... -- Patients who get the clot-busting drug alteplase (tPA) within ... who are given the drug later, Scottish doctors report. , ... better than later, but this study shows for the first ...
... ... and creates undue anxiety for women. , ... (PRWEB) May 14, 2010 -- A guide to BRCA1 and ... to equip physicians and other healthcare professionals who are not trained in genetics with ...
... ... fresh water aquatic fish habitats. With composition similar to natural rock formations, MarinePure ... , ... (PRWEB) May 14, 2010 -- CerMedia announced today at Interzoo 2010 in Nürnberg, Germany, ...
Cached Medicine News:Health News:New information on the development of the brain 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 2Health News:Early Treatment With Clot-Busting Drug Best After Stroke 3Health News:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Health News:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 3Health News:CerMedia Releases MarinePure High Surface Area Media for Aquatic Biofiltration 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: